# QUBIS

> QUBIS is a VC fund in Belfast backing Health Care and Biotechnology. See 33 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Belfast, United Kingdom
- Total investments: 33
- Last investment: May 2025
- Lead investor: 18%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/qubis-ltd-9a846067/
- X (Twitter): https://twitter.com/qubisltd
- Website: http://www.qubis.co.uk

QUBIS is a VC fund in Belfast focused on Health Care and Biotechnology. QUBIS Ltd was established in 1984 by The Queen's University of Belfast to commercialise the University's research and development activities through the formation of 'spin-out' businesses. Qubis Ltd is an investment vehicle, holding company which takes an equity holding in a new spin-out venture in return for an investment ofcash and/or Intellectual Property. Qubis Ltd 'pulls through' appropriate R & D from the laboratory into the commercial market place.

## Contacts

5 contacts available for QUBIS. Shizune tracks 12 team members at QUBIS. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/qubis?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $604k–$2.8M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 10 | 30% |
| Biotechnology | 7 | 21% |
| Medical | 5 | 15% |
| Software | 4 | 12% |
| Therapeutics | 4 | 12% |

49 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 14 | 42% |
| Funding Round | 8 | 24% |
| Venture - Series Unknown | 4 | 12% |
| Grant | 1 | 3% |
| Pre-Seed | 1 | 3% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 26 | 79% |
| United States | 2 | 6% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Denis Murphy | Team Member | 0 | https://shizune.co/investors/profile/denis-murphy |
| Gordon Bell | Director of Global | 0 | https://shizune.co/investors/profile/gordon-bell-3 |
| James O’Kane | Chairman | 0 | https://shizune.co/investors/profile/james-okane |
| Oisin Lappin | Corporate Finance Manager | 7 | https://shizune.co/investors/profile/oisin-lappin |
| Pat McComiskey | Secretary | 0 | https://shizune.co/investors/profile/pat-mccomiskey |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AMPLY Discovery | AMPLY Discovery is to develop new biological molecules for anti-infective health and nutrition applications in animal and human health. | $1.8M | Seed | May 01, 2025 |  |
| StimOxyGen | StimOxyGen specializes in developing innovative, pH-responsive nanoparticles designed to generate oxygen in hypoxic tumors. This technology aims to enhance the effectiveness of cancer treatments such as radiotherapy and chemotherapy by addressing tumor hypoxia, a significant clinical challenge. F | $1.9M |  | Mar 11, 2025 |  |
| RETìníZE | RETìníZE is an AR, VR, multi-screen installations, and software development. | $1.6M |  | Feb 25, 2025 |  |
| Dia Beta Labs | DRG labs at Ulster, maintain full access to the cutting-edge facilities on-site and its connection to a group of scholars and experts in diseases. Afterward, lead molecules for animal research are identified by advancing therapeutic candidates through our discovery platform, which uses industry-standard methodologies and models. | $1.5M | Seed | Dec 09, 2024 |  |
| GoPlugable | Airbnb for private EV charging connecting EV drivers with homes and businesses in their neighbourhood. This will help EV drivers without access to EV charging find and book slow EV chargers in their area and help more people switch to electric.GoPlugable is on a mission to create World’s largest EV charging network by connecting home and businesschargers to a private peer-to-peer network. This helps users without access to home chargers to switch to electric cars and also creates alternative base charging options for public charging, thus reducing the stress on public infrastructure.Our team stands out due to a unique combination of expertise, innovation, and community focus. Led by Maebh Reynolds, with her engineering background and strategic insight, and Andrine Mendez, known for his marketing acumen and entrepreneurial success, our leadership is both visionary and grounded. CEO Maebh Reynolds is a master's graduate in mechanical engineering with experience at Danfoss Power Solutions. Known for her contributions to EV and green mobility, she oversees customer journeys, sales, and operations. Co-founder Andrine Mendez, our CMO with 15+ years in marketing and a successful startup exit, brought the initial idea for GoPlugable. His role focuses on customer acquisition and product strategy.GoPlugable targets a £20 billion EV charging Total Addressable Market (TAM), expected to grow to £302 billion globally by 2032. We are aiming for a £396 million Serviceable Available Market (SAM) and initially focusing on a £144 million Serviceable Obtainable Market (SOM). Positioned in a market with a 31% compound annual growth rate (CAGR) over the next decade, GoPlugable is set to capture a significant share, offering substantial revenue and impact potential for our startup.GoPlugable differentiates itself in the competitive EV charging market by specializing in slow charging, unlike major providers like Tesla, BP Pulse, or Shell. Our direct competitors include Co-charger, EV Match, Joosup, Monta, and Fuuse, who offer similar services. Indirect competitors such as JustPark, Zapmap, and Plugshare list various EV charging options. Our unique selling point (USP) is our network of both business and residential slow charging points that are bookable and cost-effective compared to fast chargers. Additionally, our platform enables businesses to advertise directly to EV drivers, enhancing their visibility and customer engagement.GoPlugable has achieved notable growth with 120 host users and 450 chargee users. We've launched a successful B2B pilot in July 2024, securing our first B2B customer. Additionally, strategic partnerships with brands like Ohme, Myenergi, and SSE Airtricity have strengthened our go-to-market strategy. Overall, the platform has surpassed 1,200 downloads, demonstrating robust engagement and expanding our reach in the EV charging market. These developments are supported by £157,000 in equity-free funding and six industry awards, highlighting our innovative approach and potential within the sector. | $24.4K | Grant | Nov 02, 2023 |  |
| GenoMe Diagnostics | GenoMe Diagnostics develops OvaME product that helps in improvement of status quo of CA125 blood tests. | $1.7M | Seed | Mar 03, 2023 |  |
| Bia Analytical | Bia Analytical is a major food authentication testing laboratory, they have created industry-leading, cutting-edge food adulteration testing procedures that can help protect the whole food supply chain from food fraud and provide assurance that your products have been tested using the most advanced food fraud detection methods available. |  | Venture - Series Unknown | Jan 01, 2023 |  |
| Re-Vana Therapeutics | Re-Vana Therapeutics is a ocular pharmaceuticals & drug delivery company focused on the development and commercialisation of innovative long-acting, biodegradable drug delivery platforms to address ophthalmic conditions such as age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma and ocular infections.Their deliveryplatforms enable tailored delivery of therapeutics for long-term and can be administered by various routes to the eye. By using their platform technologies, delivery of a broad range of molecules including proteins, peptides, and small molecules can be achieved from 1 week to 1 year. The platform technologies are based on FDA-approved polymers.Their injectable platform, OcuLief™, can be tailored for the treatment of AMD and DR to achieve a long-term release of anti-vascular endothelial growth factors (anti-VEGF) or corticosteroids for 1-12 months. Their preformed platform, EyeLief™, can be tailored for the treatment of Glaucoma and retina diseases, to achieve a long-term release of small or large molecules for 6 months or more.The design strategy of Re-Vana revolves around increasing patient compliance by reducing pain and frequency of treatment, lowering side effects by controlled drug release, and cost saving for health care providers and pharmaceutical companies. | $12.1M | Series A | Nov 30, 2022 |  |
| CV6 Therapeutics | CV6 Therapeutics is a drug development company focused on the discovery, development and commercialization of novel therapies for the treatment of human diseases. | $5.7M | Venture - Series Unknown | Nov 02, 2022 |  |
| VascVersa | VascVersa is a med-tech company specializing in vascular regeneration. | $604.3K | Seed | Aug 08, 2022 |  |

10 of 33 investments shown.

## Co-investors
- [Co-FundNI](https://shizune.co/investors/profile/co-fundni) — VC Fund, 14 deals together
- [Techstart Ventures](https://shizune.co/investors/profile/techstart-ventures) — VC Fund, 10 deals together
- [Clarendon Fund Managers](https://shizune.co/investors/profile/clarendon-fund-managers) — VC Fund, 7 deals together
- [ExSight Ventures](https://shizune.co/investors/profile/exsight-ventures) — VC Fund, 6 deals together
- [Invest Northern Ireland](https://shizune.co/investors/profile/invest-northern-ireland) — VC Fund, 4 deals together
- [Visionary Venture Fund](https://shizune.co/investors/profile/visionary-venture-fund) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Medical Investors in United Kingdom](https://shizune.co/investors/medical-investors-united-kingdom)
- [Medical VC Funds in United Kingdom](https://shizune.co/investors/medical-vc-funds-united-kingdom)
- [Life Science Investors in United Kingdom](https://shizune.co/investors/life-science-investors-united-kingdom)
- [Life Science VC Funds in United Kingdom](https://shizune.co/investors/life-science-vc-funds-united-kingdom)

## FAQ

### What does QUBIS invest in?

QUBIS invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Funding Round stage. Most of the 33 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is QUBIS's check size?

QUBIS typically joins rounds of $604k–$2.8M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds QUBIS participates in.

### How do I contact QUBIS?

Public channels for QUBIS include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at QUBIS?

The team at QUBIS includes Denis Murphy (Team Member), Gordon Bell (Director of Global) and James O’Kane (Chairman), among 12 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co